Guanfacine Extended-release Tablet, Extended Release
Product Images NDC 70518-4266

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Guanfacine Extended-release (NDC 70518-4266). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line chart comparing guanfacine plasma concentration (ng/mL) over 24 hours for extended-release and immediate-release guanfacine, both dosed at 1 mg once daily. The y-axis shows plasma concentration, and the x-axis displays time in hours, illustrating pharmacokinetic profiles with extended-release maintaining lower but steadier levels versus immediate-release peaking earlier and declining more rapidly.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A chart depicting pharmacokinetic (PK) fold change and 90% confidence intervals (CI) for guanfacine extended-release when coadministered with various CYP3A4/5 inhibitors and inducers, as well as oral methylphenidate and lisdexamfetamine dimesylate. The graph shows fold changes in Cmax and AUC relative to reference for drugs including ketoconazole, fluconazole, rifampin, efavirenz, oral methylphenidate, and lisdexamfetamine dimesylate.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A forest plot chart showing the fold change and 90% confidence interval of pharmacokinetic parameters (Cmax and AUC) for oral methylphenidate and lisdexamfetamine dimesylate, displayed as change relative to a reference value.*
FDA Label Image

Figure4.jpg (Figure4)

Figure4.jpg (Figure4)
A line graph depicting treatment failure percentage over time in days for two groups: Placebo (solid line) and SPD503 (dashed line). The x-axis indicates time to treatment failure from 0 to 203 days, and the y-axis shows treatment failure percentage from 0% to 100%. The graph shows Placebo generally has a higher treatment failure rate compared to SPD503 over the study period.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Guanfacine extended-release 2 mg tablet label with a quantity of 100 per box. The label includes dosing form and strength, storage instructions, and manufacturer information listing Apotex Corp., Weston, FL. It features RemedyRepack Inc. branding and advises keeping medication out of children's reach. The label notes repackaging by RemedyRepack Inc., Indiana, PA.*
FDA Label Image

Mm2 (Guanfacine 2mg 70518 4266 01)

Mm2 (Guanfacine 2mg 70518 4266 01)
Label for Guanfacine extended-release 2 mg oral tablet, quantity of 1 tablet. Manufactured by Apotex Corp., packaged by RemedyRepack Inc. Includes prescription use statement, storage instructions, barcode, and QR code. Label emphasizes protecting tablets from moisture and not crushing, chewing, or breaking before swallowing.*
FDA Label Image

Spd503-chemical-stucture (Spd503 Chemical Stucture)

Spd503-chemical-stucture (Spd503 Chemical Stucture)
Chemical structure diagram of guanfacine hydrochloride showing its molecular connectivity, including two chlorine atoms, a carbamoyl group, and an amino group. The structure indicates the hydrochloride salt form of guanfacine.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.